JD Supra

PTAB: A Provisional Application Must Provide Written Description Support for Relied Upon

In a decision issued today, the Federal Circuit addressed the issue of whether an Examiner can rely on the filing date of a provisional application under pre-AIA 102(e) to support a rejection based on ...
JD Supra

The Provisional Patent Trap—Why Cutting Corners Can Place Startup IP Rights at Risk

For startups sensitive to cash burn rate, provisional patent applications often seem like the perfect solution—lower filing fees, simplified requirements, and a full year to file the "real" ...
IPWatchdog

CAFC Rules Provisional Application Must Support Portion of Non-Provisional Cited in Rejection to Claim Earlier Priority Date

“Clarifying its earlier holdings, the CAFC found that the provisional application must provide written description support for the specific portions of the patent specification relied upon in the ...
Seeking Alpha

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and ...
KHON2

San Jose SBDC USPTO Seminar on Demystifying the Patent Process and How To Create Quick Provisional Applications

Brent Fairbanks is a Primary Patent Examiner at the United States Patent and Trademark Office (USPTO) with a focus on data processing of sensor measurements. He serves as an Assistant Outreach ...
Nasdaq

AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses

OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset ...
Seeking Alpha

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Altamira’s polyKRAS mut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh experimental data expected to strengthen ...
Nasdaq

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative ...